Equity · Healthcare
TECH
NASDAQBio-Techne (TECH)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.
- Market cap
- 11.4B USD
- P/E (TTM)
- 65.7
- Revenue, year to Jun 2026
- 1.2B USD
- EPS, diluted, year to Jun 2026
- 1.16 USD
- 52-week range
- 43.30 USD – 72.30 USD
- Avg volume
- 1.1M
as of Aug 7, 2026
Have Bio-Techne (TECH) insiders bought or sold shares recently?
In the 90 days to 17 Nov 2026, no Bio-Techne insider bought or sold shares on the open market; all 15 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).
Form 4, 90 days to 17 Nov 2026, newest Form 4 filing 1 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 01 Nov 2026 | Hippel JamesCFO | Option exercise | 11,545 | |
| 01 Nov 2026 | Hippel JamesCFO | Tax withheld | 5,096 | 370K USD |
| 01 Nov 2026 | Kelderman KimChief Executive Officer | Tax withheld | 2,385 | 173K USD |
| 29 Oct 2026 | BAUMGARTNER ROBERT VDirector | Award | 2,750 | |
| 29 Oct 2026 | Bushman Julie LDirector | Award | 2,750 | |
| 29 Oct 2026 | HIGGINS JOHN LDirector | Award | 2,750 | |
| 29 Oct 2026 | KEEGAN JOSEPH DDirector | Award | 2,750 | |
| 29 Oct 2026 | Herr Amy E.Director | Award | 2,750 | |
| 29 Oct 2026 | Klimovsky Judith V.Director | Award | 2,750 | |
| 29 Oct 2026 | Seth AlpnaDirector | Award | 2,750 | |
| 29 Oct 2026 | Vessey RupertDirector | Award | 2,750 | |
| 28 Sep 2026 | HIGGINS JOHN LDirector | Option exercise | 15,940 |
Showing the 12 most recent of 15 compensation filings in this window. The figures above count all of them.
Which funds hold Bio-Techne (TECH)?
3 of the 45 institutional funds we track reported a Bio-Techne position for the quarter ended 30 Sep 2026 — a combined 32.6M USD; the latest of those filings landed 13 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Marshall Wace | Added | 400,184 | 29.0M USD | +347.2% |
| GAMCO Investors | Added | 36,850 | 2.7M USD | +489.6% |
| Renaissance Technologies | New position | 12,900 | 935K USD | |
| Soros Fund Management | Exited |
Have members of Congress traded Bio-Techne (TECH)?
The most recent congressional trade disclosed in Bio-Techne is a purchase by April McClain Delaney (house, MD), dated 05 Dec 2025.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 05 Dec 2025 | April McClain Delaneyhouse · Democrat–MD | Purchase | 1K USD–15K USD | 31 days |
| 22 Oct 2025 | April McClain Delaneyhouse · Democrat–MD | Purchase | 1K USD–15K USD | 13 days |
| 01 Aug 2025 | April McClain Delaneyhouse · Democrat–MD | Sale | 1K USD–15K USD | 32 days |
| 26 May 2025 | April McClain Delaneyhouse · Democrat–MD | Sale | 1K USD–15K USD | 37 days |
| 29 Apr 2025 | April McClain Delaneyhouse · Democrat–MD | Purchase | 1K USD–15K USD | 3 days |
| 09 Apr 2025 | April McClain Delaneyhouse · Democrat–MD | Purchase | 1K USD–15K USD | 23 days |
| 08 Apr 2025 | Robert P. Bresnahan, Jr.house · Republican–PA | Sale | 1K USD–15K USD | 30 days |
| 01 Apr 2025 | Julie Johnsonhouse · Democrat–TX | Sale | 1K USD–15K USD | 43 days |
What has been filed or recorded for Bio-Techne (TECH)?
The filings we hold for Bio-Techne, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Sep 2026 | Quarterly earnings | Q1 2027 reported | EPS 0.18 USD | Revenue $300M |
| 30 Sep 2026 | Financials | Total assets | 2.6B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 2.2B USD | at period end |
| 30 Jun 2026 | Annual report | FY 2026 reported | EPS 1.16 USD | Revenue $1.22B |
| 30 Jun 2026 | Financials | Revenue | 1.2B USD | fiscal year |
| 30 Jun 2026 | Financials | Net income to common shareholders | 181.8M USD | fiscal year |
| 30 Jun 2026 | Financials | Diluted EPS | 1.16 USD | fiscal year |
| 31 Mar 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.32 USD | Revenue $311M |
| 31 Dec 2025 | Quarterly earnings | Q2 2026 reported | EPS 0.24 USD | Revenue $296M |
| 30 Sep 2025 | Quarterly earnings | Q1 2026 reported | EPS 0.24 USD | Revenue $287M |
| 30 Jun 2025 | Annual report | FY 2025 reported | EPS 0.46 USD | Revenue $1.22B |
| 31 Mar 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.14 USD | Revenue $316M |
| 31 Dec 2024 | Quarterly earnings | Q2 2025 reported | EPS 0.22 USD | Revenue $297M |
What do people ask about Bio-Techne (TECH)?
What is Bio-Techne’s market cap?11.4B
Bio-Techne is worth 11.4B USD by market value as of 7 Aug 2026, which is the share price times the shares on issue from its SEC filings.
What is Bio-Techne’s P/E ratio?65.7
Bio-Techne has a price-to-earnings ratio of 65.7, as of 7 Aug 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Bio-Techne’s revenue?1.2B
Bio-Techne reported revenue of 1.2B USD for the year ended 30 Jun 2026, as filed with the SEC. See Filings
Have Bio-Techne insiders bought or sold shares recently?15 filings
In the 90 days to 17 Nov 2026, no Bio-Techne insider bought or sold shares on the open market; all 15 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4). See Insiders
Which funds own Bio-Techne?3 of 45
3 of the 45 funds we track reported a Bio-Techne position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Marshall Wace, GAMCO Investors and Renaissance Technologies. See Funds
Have members of Congress traded Bio-Techne?9 trades
Yes. 9 trades in Bio-Techne appear in the congressional disclosures we hold; the latest is a purchase by April McClain Delaney (House, MD) dated 5 Dec 2025, filed 5 Jan 2026. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Bio-Techne last report earnings?0.18
Bio-Techne last reported earnings on 30 Sep 2026 for Q1 2027, with EPS of 0.18 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Robert P. Bresnahan, Jr.: House Creative Services, Public domain; April McClain Delaney: Ike Hayman, House Creative Services, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings